Form 4: Caribou Biosciences Director Natalie Sacks Acquires Options

Director Natalie Sacks acquired options to purchase 40,500 shares of Caribou Biosciences stock at $1.41 per share.

Summary

• On February 20, 2025, Natalie Sacks, a director of Caribou Biosciences, Inc., was granted an option to purchase 40,500 shares of common stock.
• The exercise price of the option is $1.41 per share.
• The options vest monthly, with one-twelfth of the shares vesting on each monthly anniversary of the grant date, and will be fully vested by February 20, 2026, contingent upon continued service to the issuer.
• The option expires on February 19, 2035.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to a director. It doesn't inherently indicate positive or negative performance, but rather transparency in insider transactions.

Positives

• The acquisition of options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the vesting schedule is contingent on continued service to the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for directors and officers of publicly traded companies when they have transactions involving the company's securities. It reflects insider activity, which is closely monitored by investors.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company director.

Key Dates

Keywords

Caribou Biosciences, CRBU, Natalie Sacks, Director, Option, Stock, Acquisition, Vesting